HomeAI · summaries
Storia in 2 fonti
Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages highlight US portfolio strength, new launches like Unloxcyt, and a steady margin outlook despite higher R&D spending, with EBITDA growth supported by diversified global business momentum outlook
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages…
- ·
Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend
Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore…
- ·
thehindubusinessline.com
Sun Pharma Q4 net profit up 26% at ₹2,714 crore
Sun Pharma's Q4 net profit rises 26% to ₹2,714 crore, driven by robust formulation sales and strong overall revenue growth.
- ·
Sun Pharma Q4 net profit up 26 per cent
Sun Pharma reports a 26% rise in Q4 net profit, driven by strong sales and ongoing investments in innovative products.
- ·
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal
Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on…